OBJECTIVE: To probe into the occurrence and characteristics of hyperkalemia induced by the immunosuppressant tacrolimus

so as to provide references for clinical safe medication. METHODS: Literature of hyperkalemia induced by tacrolimus collected in domestic and foreign databases were retrospectively studied as of Sept.21 st

2020. Clinical data were statistically analyzed. RESULTS: Hyperkalemia induced by tacrolimus was the relatively common electrolyte disorder. A total of 18 valid case reports were screened

including 41 patients. The occurrence of hyperkalemia might be related to the doses of drugs and types of transplantation. When hyperkalemia occurred

it was recommended to carry out symptomatic treatment in time and reduce the dose of tacrolimus or adjust the immunosuppressive treatment regimen. CONCLUSIONS: In order to avoid and reduce the occurrence of hyperkalemia

medication monitoring should be strengthened during the clinical application of tacrolimus.